Prescription of extended-duration thromboprophylaxis after high-risk, abdominopelvic cancer surgery.

ABSTRACT:

Objective

Extended-duration thromboprophylaxis for 4weeks after discharge has been demonstrated to reduce venous thromboembolic events (VTE) in cancer patients undergoing abdominopelvic surgery and is recommended in national guidelines. We examined the utilization and effectiveness of extended-duration low molecular weight heparin prophylaxis in high-risk cancer patients.

Methods

We analyzed patients with colon, ovarian, and uterine cancer who underwent surgery from 2009 to 2013 and who were recorded in the MarketScan database. Multivariable models and propensity score analysis with inverse probability of treatment weight were developed to examine uptake and predictors of use of post-discharge low molecular weight heparin (LMWH), as well as associated adverse events (transfu

SUBMITTER: Wright JD 

PROVIDER: S-EPMC4877256 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature